{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Of+Esophagus", "query": { "condition": "Adenocarcinoma Of Esophagus" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 324, "total_pages": 33, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Of+Esophagus&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T19:30:08.298Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05591053", "title": "Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Esophagus Cancer", "Esophageal Cancer", "Esophageal Neoplasms", "Esophageal Diseases", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Esophagus SCC", "Esophagus Tumor", "Esophagus Adenocarcinoma", "Esophagus Neoplasm" ], "interventions": [ { "name": "ActivSight", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Activ Surgical", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2023-04-01", "completion_date": "2025-01", "has_results": false, "last_update_posted_date": "2024-02-21", "last_synced_at": "2026-10-04T19:30:08.298Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05591053" }, { "nct_id": "NCT01961778", "title": "Comparison of Treatments for Barrett's Esophagus With High-Grade Dysplasia/Early Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Barrett's Esophagus" ], "interventions": [ { "name": "Radio-Frequency Ablation", "type": "DEVICE" }, { "name": "Cryotherapy", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "21 Years to 99 Years" }, "enrollment_count": 50, "start_date": "2013-11", "completion_date": "2020-02-01", "has_results": false, "last_update_posted_date": "2022-01-12", "last_synced_at": "2026-10-04T19:30:08.298Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01961778" }, { "nct_id": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Carcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Esophageal Adenocarcinoma", "Cholangiocarcinoma", "Gallbladder Carcinoma" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-09-15", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-04T19:30:08.298Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04430738" }, { "nct_id": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "Metastatic Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "Zongertinib", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "zanidatamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 768, "start_date": "2024-06-28", "completion_date": "2029-01-08", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-04T19:30:08.298Z", "location_count": 26, "location_summary": "Cerritos, California • Los Angeles, California • Orange, California + 18 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06324357" }, { "nct_id": "NCT00077545", "title": "3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Esophagus", "Recurrent Esophageal Cancer", "Stage IV Esophageal Cancer" ], "interventions": [ { "name": "triapine", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2004-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-10-08", "last_synced_at": "2026-10-04T19:30:08.298Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077545" }, { "nct_id": "NCT00524186", "title": "Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "sunitinib malate", "type": "DRUG" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 23, "start_date": "2007-05", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-06-21", "last_synced_at": "2026-10-04T19:30:08.298Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524186" }, { "nct_id": "NCT01183559", "title": "A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer of the Esophagus", "Adenocarcinoma of the Gastroesophageal Junction", "Cancer of the Stomach" ], "interventions": [ { "name": "Vandetanib", "type": "DRUG" }, { "name": "5 Fluorouracil (FU)", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "External Beam Radiation Therapy (RT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2008-08-07", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2021-01-22", "last_synced_at": "2026-10-04T19:30:08.298Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183559" }, { "nct_id": "NCT00448760", "title": "Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Floxuridine", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Microarray analysis", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "Conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "GENETIC", "PROCEDURE" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 29, "start_date": "2004-10", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-10-04T19:30:08.298Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00448760" }, { "nct_id": "NCT01868139", "title": "Spray Cryotherapy for Esophageal Cancer (ICE-CANCER)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "Liquid nitrogen spray cryotherapy with the truFreeze device", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2013-06", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2022-03-07", "last_synced_at": "2026-10-04T19:30:08.298Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01868139" }, { "nct_id": "NCT00093652", "title": "Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "gefitinib", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2003-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-10-06", "last_synced_at": "2026-10-04T19:30:08.298Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00093652" } ] }